MedPath

A Clinical Trial to study the effect of tablet Vyoshadi guggulu along with the Vaitarana Basti protocol in Rheumatoid Arthritis.

Phase 1/2
Not yet recruiting
Conditions
Rheumatoid arthritis with rheumatoid factor, unspecified. Ayurveda Condition: AMAVATAH,
Registration Number
CTRI/2023/06/054110
Lead Sponsor
Dr Nagashree N
Brief Summary

This study is a Open label Controlled Clinical trial  to evaluate the Combined Clinical effect of Vyoshadi Guggulu along with Vaitarana Basti protocol in the Disease Activity of Rheumatoid arthritis. Subjects are allocated in to study and control groups respectively.

**Study group** includes 15 subjects Qualifying the Inclusion Criteria of the current study with Oral administration of Tab. Vyoshadi guggulu 500mg TID with lukewarm water After food for 31 days starting from Day-1 of the trial along with Vaitarana basti Protocol in the Yoga Basti pattern which includes alternate 5 Anuvasana basthi with Bruhat Saindhavadi taila and 3 Niruha basti, starting from Anuvasana basti which is given on consecutive days respectively ending with two Anuvasana basti for about 8 days (From Day 8- Day 15 of the trial period).

**Control group** includes 15 subjects Qualifying the Inclusion Criteria of the current study with Oral administration of Tab. Simhanada guggulu 500mg TID with lukewarm water After food for 31 days starting from Day-1 of the trial along with Vaitarana basti Protocol in the Yoga Basti pattern which includes alternate 5 Anuvasana basthi with Bruhat Saindhavadi taila and 3 Niruha basti, starting from Anuvasana basti which is given on consecutive days respectively ending with two Anuvasana basti for about 8 days (From Day 8- Day 15 of the trial period).

The **Primary Outcome measure** will be Simple Disease Activity Index (SDAI) of Rheumatoid Arthritis after 31 days.

The **Secondary Outcome measure** will be QoL- RA (Quality of Life- Rhematoid Arthritis) Questionnaire after 31 days.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

American College of Rheumatology/ European League against Rheumatism classification criteria for Rheumatoid Arthritis 2010, Subjects who fulfills a score of greater than or equal to 6/10 with Duration of symptoms greater than or equal to 6 weeks and Lesser than or equal to 10 years.

Exclusion Criteria
  • Subjects, 1.On drug therapy such as DMRAD’s.
  • 2.With Severe joint deformity.
  • 3.Diagnosed with Spine, Gout, Ankylosing spondylosis, Osteoarthritis, Traumatic arthritis, Psoriatic arthritis, Infective Arthritis, Septic arthritis and Pyogenic Osteomyelitis.
  • 4.With associated co-morbidities such as Cardiac disease, Pulmonary Tuberculosis, Uncontrolled Diabetes Mellitus, Malignant Hypertension, Renal Function Impairment.
  • 5.Pregnant and Lactating Women.
  • 6.Contraindicated for Basthi procedure.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Simple Disease Activity Index (SDAI) of Rheumatoid Arthritis.Day-0 & Day-32
2.Pratyatma Lakshanas Of Amavata.Day-0 & Day-32
Secondary Outcome Measures
NameTimeMethod
QoL- RA (Quality of Life- Rhematoid Arthritis) QuestionnaireDay-0 & Day-32

Trial Locations

Locations (1)

Sri Dharmasthala Manjunatheshwara Institute of Ayurveda and Hospital, Anchepalya, Bengaluru

🇮🇳

Bangalore, KARNATAKA, India

Sri Dharmasthala Manjunatheshwara Institute of Ayurveda and Hospital, Anchepalya, Bengaluru
🇮🇳Bangalore, KARNATAKA, India
Dr Nagashree N
Principal investigator
08217862736
nagashreen@sdmayurbangalore.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.